StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a report released on Wednesday. Separately, Piper Sandler raised their price target on shares of Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an overweight rating in a research report on Thursday, November 9th. […]